Vera Therapeutics, Inc.
VERA · Nasdaq · United States
Share price · VERA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VERA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 14 Aug 2026+9.5%
Nothing announced by VERA that day or the session before.
- 4 Aug 2026-7.1%
Nothing announced by VERA that day or the session before.
- 16 Jul 2026-8.0%
Nothing announced by VERA that day or the session before.
- 22 Jun 2026+9.5%
Nothing announced by VERA that day or the session before.
- 18 May 2026-8.0%
Nothing announced by VERA that day or the session before.
- 13 May 2026+6.7%
Nothing announced by VERA that day or the session before.
- 10 Apr 2026+10.0%
Nothing announced by VERA that day or the session before.
- 19 Mar 2026+8.0%
Nothing announced by VERA that day or the session before.
- 11 Mar 2026+4.4%
Nothing announced by VERA that day or the session before.
Share of unusual movement by asset
For each asset, the share of VERA's own-move activity since 13 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | BLyS/APRIL (B-cell activating factor/a proliferation-inducing ligand)Protein / enzyme therapeutic | IgA Nephropathy |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $10M | $41M | $55M+ $329M short-term inv. | $94M-$99M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $60M | $49M+ $450M short-term inv. | $109M-$100M operating cash flow | report ↗ |
| 2026-Q1 | — | $86M | $114M+ $482M short-term inv. | $121M-$107M operating cash flow | report ↗ |
| 2025-Q3 | — | $56M | $58M+ $440M short-term inv. | $80M-$62M operating cash flow | report ↗ |
| 2025-Q2 | — | $58M | $49M+ $508M short-term inv. | $77M-$55M operating cash flow | report ↗ |
| 2025-Q1 | — | $41M | $55M+ $535M short-term inv. | $52M-$54M operating cash flow | report ↗ |
| 2024-Q3 | — | $40M | $27M+ $326M short-term inv. | $47M-$37M operating cash flow | report ↗ |
| 2024-Q2 | — | $29M | $25M+ $359M short-term inv. | $34M-$25M operating cash flow | report ↗ |
| 2024-Q1 | — | $23M | $69M+ $335M short-term inv. | $28M-$34M operating cash flow | report ↗ |
| 2023-Q3 | — | $16M | $27M+ $133M short-term inv. | $20M-$23M operating cash flow | report ↗ |
| 2023-Q2 | — | $16M | $34M+ $147M short-term inv. | $20M-$18M operating cash flow | report ↗ |
| 2023-Q1 | — | $25M | $138M+ $60M short-term inv. | $30M-$26M operating cash flow | report ↗ |
| 2022-Q3 | — | $20M | $31M+ $84M short-term inv. | $25M-$18M operating cash flow | report ↗ |
| 2022-Q2 | — | $10M | $51M+ $82M short-term inv. | $15M-$19M operating cash flow | report ↗ |
| 2022-Q1 | — | $13M | $112M+ $39M short-term inv. | $17M-$9.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $215M | $355M+ $360M short-term inv. | $75M-$241M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $126M | $93M+ $548M short-term inv. | $38M-$135M operating cash flow | report ↗ |
| 2023-FY | — | $78M | $46M+ $115M short-term inv. | $24M-$92M operating cash flow | report ↗ |
| 2022-FY | — | $69M | $44M+ $71M short-term inv. | $22M-$68M operating cash flow | report ↗ |
| 2021-FY | — | $22M | $80M+ $0 short-term inv. | $8.2M-$24M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($250K), 32 sales ($11.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-15 | Fordyce Marshall · director, PRESIDENT AND CEO | Option exercise | 18,500 | $2.90 | $54K | Form 4 |
| 2026-09-15 | Fordyce Marshall · director, PRESIDENT AND CEO | Open-market sale | 18,500 | $37.00 | $685K | Form 4 |
| 2026-09-15 | Fordyce Marshall · director, PRESIDENT AND CEO | Option exercise (derivative) | 18,500 | — | — | Form 4 |
| 2026-09-11 | Young Joseph R · SVP, FINANCE, CHIEF ACCT OFFCR | Option exercise | 5,000 | $3.94 | $20K | Form 4 |
| 2026-09-11 | Young Joseph R · SVP, FINANCE, CHIEF ACCT OFFCR | Option exercise (derivative) | 5,000 | — | — | Form 4 |
| 2026-09-02 | Fordyce Marshall · director, PRESIDENT AND CEO | Option exercise | 18,500 | $2.90 | $54K | Form 4 |
| 2026-09-02 | Fordyce Marshall · director, PRESIDENT AND CEO | Open-market sale | 18,500 | $35.12 | $650K | Form 4 |
| 2026-09-02 | Fordyce Marshall · director, PRESIDENT AND CEO | Option exercise (derivative) | 18,500 | — | — | Form 4 |